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Abstract
Background: High-grade osteosarcoma is a primary malignant bone tumor mostly occurring in adolescents and
young adults, with a second peak at middle age. Overall survival is approximately 60%, and has not significantly
increased since the introduction of neoadjuvant chemotherapy in the 1970s. The genomic profile of high-grade
osteosarcoma is complex and heterogeneous. Integration of different types of genome-wide data may be advantageous
in extracting relevant information from the large number of aberrations detected in this tumor.
Methods: We analyzed genome-wide gene expression data of osteosarcoma cell lines and integrated these data with a
kinome screen. Data were analyzed in statistical language R, using LIMMA for detection of differential expression/
phosphorylation. We subsequently used Ingenuity Pathways Analysis to determine deregulated pathways in both
data types.
Results: Gene set enrichment indicated that pathways important in genomic stability are highly deregulated in
these tumors, with many genes showing upregulation, which could be used as a prognostic marker, and with
kinases phosphorylating peptides in these pathways. Akt and AMPK signaling were identified as active and
inactive, respectively. As these pathways have an opposite role on mTORC1 signaling, we set out to inhibit Akt
kinases with the allosteric Akt inhibitor MK-2206. This resulted in inhibition of proliferation of osteosarcoma cell
lines U-2 OS and HOS, but not of 143B, which harbors a KRAS oncogenic transformation.
Conclusions: We identified both overexpression and hyperphosphorylation in pathways playing a role in genomic
stability. Kinome profiling identified active Akt signaling, which could inhibit proliferation in 2/3 osteosarcoma cell
lines. Inhibition of PI3K/Akt/mTORC1 signaling may be effective in osteosarcoma, but further studies are required
to determine whether this pathway is active in a substantial subgroup of this heterogeneous tumor.
Keywords: Osteosarcoma, Tumor cell lines, Kinome profiling, Gene expression profiling, Genomic instability,
Bone tumor
Background
High-grade osteosarcoma is the most prevalent primary
malignant bone tumor. Most frequently, the long bones
of adolescents and young adults are affected, with a
yearly incidence of approximately 5 cases per million per
year [1]. Patients are generally treated with high doses of
neoadjuvant chemotherapy to prevent the outgrowth of
micrometastases. In 15-25% of all patients, however, meta-
static disease is clinically detectable at diagnosis and des-
pite the intensive treatment, 45% of all patients develop
distant metastases, the leading cause of death of osteo-
sarcoma patients [2,3]. The introduction of neoadjuvant
chemotherapy in the 1970s has increased survival from
10-20% to approximately 60%. However, survival has
reached a plateau, and new treatments are urgently needed
[4-6]. Osteosarcoma is an extremely genomically unstable
tumor, with karyotypes harboring numerous numerical
and structural changes [7,8]. In addition, osteosarcoma
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both intra- and intertumoral. Both the complex genotype
and its heterogeneity render it difficult to determine which
genomic alterations are important in osteosarcomagenesis,
as not all alterations may lead to a difference in mRNA,
protein levels, or enzyme activity in the tumor tissue. Inte-
gration of different data types is therefore of particular
relevance for studying a heterogeneous tumor with a com-
plex genomic profile such as osteosarcoma. Genomic and
expression data of osteosarcoma tumor samples have been
integrated by different groups, and many of the reported
recurrent osteosarcoma driver genes play a role in cell
cycle regulation and maintenance of genomic stability
[9,10]. Yet, even though recurrent driver genes may pro-
vide knowledge on what pathways are affected that help
tumor cells survive, such driver genes may not always be
accessible as targets for treatment. This especially holds
for pathways involved in genetic stability, since the dam-
age is already done.
Oncogenic kinases are often active in tumor cells, and
a number of kinases can be pharmacologically inhibited.
Therapies targeting oncogenic kinases have provided
promising results in inhibiting proliferation of cancer
cells, and some kinases have been targeted in preclinical
and clinical studies in childhood sarcomas (as reviewed
in Wachtel et al. [11]), e.g. IGF1R and mTOR [12,13].
An unbiased approach to identify active kinases in can-
cer is to perform kinome-wide screens. Such screens
have previously been effectively used in other types of
sarcoma and have led to the detection of specific targets
for treatment [14,15]. As combining the analysis of dif-
ferent data types using systems biology approaches can
give a more complete impression of the state of a tumor
cell, we set out to integrate genome-wide gene expres-
sion data of osteosarcoma cell lines with kinome profil-
ing data. Osteosarcoma cell lines are widely available
and have been shown to be representative for the tumor
of origin, both on a genome-wide as on a functional
level, and are therefore a good model to study osteosar-
coma preclinically [9,16].
We previously have performed genome-wide expression
analysis on a panel of 19 osteosarcoma cell lines [17]. In
the present study, we compared these expression profiles
with the different putative progenitor cells of osteosarcoma
– mesenchymal stem cells (MSCs) and osteoblasts – in
order to define the common denominator pathways that
are deregulated in osteosarcoma. We then integrated ex-
pression data with a serine/threonine (Ser/Thr) kinome
screen, to determine whether pathways with enrichment
of differentially expressed genes show enrichment in of
hyperphosphorylation as well. In order to detect overactive
kinases in osteosarcoma, which may be potential targets
for treatment, we identified the most significant pathways
by a single-way analysis of the kinome profiling data.
Methods
Cell culture
Osteosarcoma cell lines were previously characterized
and described [17]. Human bone-marrow-derived MSCs
were obtained from two osteosarcoma patients, and were
characterized and handled as described [18]. For kinome
profiling of osteosarcoma versus MSCs, cells were cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM;
Invitrogen, Carlsbad, CA, USA), supplemented with 10%
fetal bovine serum (Greiner Bio-one, Frickenhausen,
Germany), in order to eliminate differences in kinase ac-
tivity caused by culture conditions. For inhibition experi-
ments and kinome profiling of inhibition experiments,
osteosarcoma cell lines 143B, U-2 OS, and HOS were
maintained in RPMI 1640 supplemented with 10% fetal
calf serum (both from Invitrogen, Carlsbad, CA). The hu-
man pre-B acute lymphoblastic leukemia cell line NALM-
6 cell line was kindly provided by Mw. N. Duinkerken
(Department of Hematology, Leiden University Medical
Center, the Netherlands), and was maintained in Iscove’s
Modified Dulbecco’sM e d i u m( I M D M )s u p p l e m e n t e d
with GlutaMAX-1 (Life Technologies, Carlsbad, CA) and
10% fetal bovine serum (Greiner Bio-one, Frickenhausen,
Germany). All cells were regularly tested for mycoplasm
and were genotyped before and after experiments using the
Powerplex 1.2 system (Promega, Leiden, the Netherlands),
as described previously [16], and using CellID STR profil-
ing (Promega, Leiden, the Netherlands). Latest genotyping
results are added in Additional file 1). Cell lines corre-
sponded to the entries in the ATCC (www.atcc.org) and
DSMZ (www.dsmz.de) databases.
Cell lysates
Kinome profiling was performed on osteosarcoma cell
lines 143B and U-2 OS and on two MSCs – MSC001
and MSC006. Cells at 80% confluence were washed
twice with Phosphate buffered Saline and lysed with M-
PER Mammalian Extraction Buffer, supplemented with
Halt Phosphatase Inhibitor Cocktail and EDTA free Halt
Protease Inhibitor Cocktail (Pierce Biotechnology, Rock-
ford, IL), according to the manufacture’s protocol. Cells
were incubated on ice for at least 30 minutes before
collecting the lysates and centrifuging these for 15 mi-
nutes at 4°C at> 10,000× g. Protein concentration was
measured using a detergent-compatible Protein Assay
(Bio-Rad Laboratories, Hercules, CA) according to the
manufacturer’s protocol. Samples were snap-frozen
and stored at −70°C.
Proliferation assays
MK-2206 was dissolved in DMSO at a concentration of
10 mM and stored at −20°C. For 143B, U-2 OS, and
HOS, 2,000, 4,000, and 2,000 cells/well respectively, were
plated in a 96-wells plate. NALM-6, a human pre-B
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cluded as a positive control, as ALL cell lines have been
shown to be highly sensitive to MK-2206 [19]. This cell line
g r o w si ns u s p e n s i o na n dw a sp lated at 50,000 cells/well.
After 24 hrs, MK-2206 was added in triplicate in different
concentrations – 0 nM, 0.5 nM, 1 nM, 5 nM, 10 nM,
50 nM, 100 nM, 500 nM, 1 μM, 5 μM, and 10 μM. For
143B and HOS, the effect of concentrations of 2, 3, 4, and
5 nM was assessed as well. Cells were grown in the pres-
ence of inhibitor for 120 hours. Cell proliferation was
determined by incubating the cells with reagent WST-1
(Roche, Basel, Switzerland) for 2 hrs and subsequently
measured using a Wallac 1420 VICTOR2 (Perkin Elmer,
Waltham, MA). Data were analyzed in Graphpad Prism
5.01 (www.graphpad.com). Relative IC50sw e r ec a l c u l a t e d
using results from the different concentrations up to the
highest dose where toxicity was not yet present. The re-
sults shown are representative results from at least three
independent experiments.
Genome-wide gene expression profiling
We analyzed our previously published data of osteosar-
coma cell lines (n =19), MSCs (n= 12), and osteoblasts
(n =3) (GEO superseries, accession number GSE42352)
[9]. Microarray data processing and quality control were
performed in the statistical language R version 2.15 [20]
as described previously [21].
Kinome profiling
Kinome profiling was performed on 1 μg of cell lysate
on the serine/threonine (Ser/Thr) Kinase PamChip® peptide
microarrays (PamGene,‘s-Hertogenbosch, the Netherlands)
according to the manufacturer’s protocol, essentially as
described in Hilhorst et al. [22]. This peptide microarray
comprises 142 peptide sequences derived from human
phosphorylation sites. Peptide phosphorylation is detected
in time with a mixture of fluorescently labeled anti-
phosphoserine/threonine antibodies. We used at least
three technical replicates for each MSC line, and four
technical replicates for the osteosarcoma cell lines. Images
were taken every 5 minutes, over the course of 60 minutes.
Signal quantification on phosphorylated peptides was per-
formed in BioNavigator software (PamGene International,‘s
Hertogenbosch, the Netherlands). Subsequently, data were
normalized in R [23] using the vsn package [24]. Median
signals at 60 minutes of incubation with the cell lysates
were analyzed in Bioconductor [25] package array Quality-
Metrics [26] to identify poor quality samples, which were
removed from further analysis. Technical replicates of
good quality were averaged. To determine whether these
data were reproducible, we analyzed data from different
cycles (0, 10, 20, 30, 40, 50, and 60 minutes incubation
with cell lysates).
In the second kinome profiling experiment we com-
pared lysates of untreated cells with lysates of cells treated
with MK-2206. Different treatment durations and concen-
trations were used – no treatment, treatment for 5, 30,
180, and 960 minutes with 1 μM MK-2206, and treatment
for 180 minutes with 10 μM of the drug. Kinome profiling
was performed as described above, with the difference that
we used 1–5 technical replicates per condition. Of this ex-
periment, we analyzed signals at 30 minutes of incubation
with the lysates.
Statistical analyses of microarray data
We performed LIMMA analysis [23] in order to determine
differential mRNA expression between osteosarcoma cell
lines (n=19) and control cell lines – MSCs (n=12) and
osteoblasts (n=3) and to determine differential phosphor-
ylation of peptides on the PamChip® microarray between
osteosarcoma cell lines (n=2) and MSCs (n=2). We used
a Benjamini and Hochberg False Discovery Rate (FDR) of
0.05 as cut-off for significance. Kinome profiling signals
obtained for the different treatment conditions were ana-
lyzed in a paired approach, in which signals from un-
treated cells were subtracted from the signals from treated
cells. For both kinome profiling experiments, we used a
cut-off of 0.1 for the absolute log fold change (logFC).
Heatmaps were generated using the function heatmap.2
of R package gplots.
Pathway analysis
In order to reveal pathways which were significantly af-
fected on mRNA levels in osteosarcoma cell lines, we
intersected the toptables obtained by LIMMA analysis of
osteosarcoma cell lines versus MSCs and of osteosar-
coma cell lines versus osteoblasts. Gene symbols for all
probes were imported into the software Ingenuity Path-
ways Analysis (IPA, Ingenuity Systems, www.ingenuity.
com), together with FDR adjusted P-values (adjP) and
average logFCs. Only the gene symbols of probes that
were both significantly upregulated or both significantly
downregulated in osteosarcoma cell lines as compared
with MSCs and with OBs (adjP<0.05) were selected to
be considered as significantly differentially expressed in the
IPA analysis. For differential phosphorylation, we imported
the results from the LIMMA analysis on kinome profiling
data, with a cut-off of 0.05 for adjusted P-value and a
cut-off of 0.1 for logFC. The significance of the associ-
ation between the data set and the canonical pathways
was measured as described previously [27]. Pathways
with adjP < 0.05 were considered to be significantly af-
fected. In addition, transcription factor analyses were
performed on gene expression data in IPA in order to
predict activated or inhibited transcription factors based
on expression of target genes, returning p-values (with a
cut-off of 0.05 for significance) and regulation z-scores.
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Genome-wide gene expression profiling of high-grade
osteosarcoma cell lines
We started by comparing gene expression signatures of
19 osteosarcoma cell lines, 12 MSC, and 3 osteoblast
cultures using unsupervised hierarchical clustering. Two
separate clusters were detected – one containing all
tumor cell samples and one containing control samples.
Within the control sample cluster, osteoblasts clustered
separately from MSCs (Additional file 2). LIMMA ana-
lysis resulted in 7,891 probes encoding for differentially
expressed (DE) genes between osteosarcoma cell lines
and MSCs, and 2,222 probes encoding for DE genes be-
tween osteosarcoma cells and osteoblasts (Additional file 3).
Intersecting of these gene lists showed 1,410 probes that
were significant in both analyses, of which 1,390 were upreg-
ulated in both analyses, or downregulated in both analyses
(Figure 1). These probes, encoding for 1,312 genes, were
selected for subsequent pathways analysis, in order to de-
termine commonly affected pathways in osteosarcoma
tumor cells.
Gene expression is altered in pathways regulating
genomic stability
Pathway analyses on the 1,312 differentially expressed genes
resulted in 17 significantly affected pathways (Figure 2).
14 out of these 17 pathways play a direct or indirect role
in genomic stability. Unsupervised hierarchical cluster-
ing of all cell line data and data from 84 osteosarcoma
biopsies (GEO accession number GSE33382, [9]) was
performed on all DE genes present in these 17 signifi-
cantly affected pathways, which resulted in a cluster of
control cells and biopsies, and larger cluster of osteosar-
coma cell lines and biopsies (Additional file 4). Patients
whose biopsies had expression profiles of these path-
ways similar to osteosarcoma cell lines showed worse
metastasis-free survival than patients with intermediate
expression profiles, and than patients whose biopsies
had expression profiles more similar to the control cul-
tures, i.e. non-transformed primary mesenchymal cell
cultures and osteoblast cultures (log-rank test for trend,
P =0.049, Additional file 5). Transcription factors that
were predicted to be activated or inhibited based on ex-
pression of target genes are shown in Additional file 6.
The most activated transcription factor was MYC,w h i l e
the most inactivated transcription factor was TP53.
Kinome profiling of osteosarcoma cell lines
To obtain more information on the activity of the path-
ways which showed aberrant mRNA expression, we inte-
grated mRNA expression data with data obtained with
kinase PamChip® peptide microarrays. These peptide mi-
croarrays were incubated with lysates of the osteosar-
coma cell lines 143B and U-2 OS, two of the most
widely used osteosarcoma cell lines, of which 143B is the
only human osteosarcoma cell line with metastatic be-
haviour in a mouse xenograft model [16], and with ly-
sates of two human MSC cultures. Kinases present in
the cell lysates can, in the presence of ATP, phosphoryl-
ate the peptides present on the microarray, which is de-
tected by fluorescently labeled antibodies. We compared
kinome profiling data at different incubation times by
intersecting lists of differentially phosphorylated peptides
between osteosarcoma cells and MSCs, obtained by
LIMMA analyses, as shown in Additional file 7. This
data analysis demonstrated a large overlap in the de-
tected differentially phosphorylated peptides, and a
build-up of differentially phosphorylated peptides over
time. Most peptides showed differential phosphorylation
after 20 minutes of incubation with cell lysates. After 60
minutes of incubation on the peptide microarray, 49
peptides were detected to be significantly differentially
phosphorylated between osteosarcoma cell lines and
mesenchymal stem cells. These peptides are represented
in Figure 3. As a reference, we performed an unsupervised
hierarchical clustering including all technical replicates
(Additional file 8), which showed that phosphorylation of
peptides by cell lysates of most technical replicates was
comparable.
1390
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Figure 1 Intersection of top lists. Venn diagram showing the
significant probes in the analysis of osteosarcoma cell lines vs MSC
(vsMSC) and vs osteoblasts (vsOB), and the intersection of these
significant probes with the subset of all probes (both significant and
nonsignificant) that shows both up- or both downregulation in
these two analyses (same sign). In total, 1,410 probes are significant
in both analyses, of which 1,390 have the same sign of logFC.
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The significance of the 17 pathways that were returned
from the pathway analysis on mRNA expression data
was tested on kinome profiling results in IPA. In total,
7/17 pathways were significant in kinome profiling as
well. These seven pathways were a subset of the 14 path-
ways with a known role in genomic stability and cell
cycle progression. Most significantly differentially phos-
phorylated peptides in these seven pathways showed
higher phosphorylation levels in osteosarcoma cell lines
(Figure 4), indicating that kinases affect phosphorylation
of molecules playing a role in genomic stability and cell
cycle progression.
PI3K/Akt and AMPK signaling in osteosarcoma
Unsupervised pathway analysis on the kinome profiling
results returned the IPA pathway PI3K/Akt signaling as
the most significantly affected pathway in osteosarcoma
cells (Figure 5) and the AMPK pathway as second most
significantly affected pathway (Additional file 9). Specif-
ically, molecules directly downstream of Akt kinases
showed higher phosphorylation in osteosarcoma than in
MSCs, while molecules downstream of AMPK showed
lower phosphorylation levels. As these results indicate
that Akt signaling is active in osteosarcoma and might
be driving its high proliferative capacity, we set out to
pharmacologically inhibit Akt using the compound
MK-2206.
MK-2206 inhibits proliferation of U-2 OS and HOS, but
not of 143B
We inhibited osteosarcoma and control cells for 120 h
with MK-2206, an allosteric inhibitor of all three Akt fam-
ily members. Inhibition of the positive control leukemia
Figure 2 Significantly affected pathways in osteosarcoma cells. Stacked bar chart depicting all significantly affected pathways as identified
by gene expression profiling of osteosarcoma cell lines, showing percentages of up- (red), downregulated (green), not significantly altered genes
(gray), and genes which were not present on the microarray (white). The –log(adjP)( −log(B-H) p-value) is plotted in orange, and is above 1.3
for adjP<0.05.
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with MK-2206 was dose-dependent, with IC50so f
0.38 μM and 2.5 μM, and maximal responses of 94% and
71%, respectively (Figure 6). 143B did not show any re-
sponse at concentrations below 5 μM. Because 143B ex-
hibits an oncogenic KRAS transformation [28], we assessed
MK-2206 specificity on the parental cell line of 143B, HOS,
which has not been KRAS transformed. HOS indeed
responded similar to U-2 OS, with an IC50 of 2.6 μMa n d
maximal response of 62%.
Different phosphorylation patterns upon treatment with
MK-2206
As 143B and U-2 OS showed different sensitivities to
MK-2206, we performed a paired analysis between
kinome profiling data obtained from lysates of cells,
which were treated with different concentrations of
MK-2206, and for different treatment lengths. Over-
all, the phosphorylation patterns differed between
both cell lines, and distances between treatment op-
tions within each cell line were smaller than between
the cell lines (Additional file 10). We generated a
heatmap of differential phosphorylation in the paired
analysis of treated and untreated cells, depicting all
peptides of the PamGene chip which are downstream
of PI3K/Akt (Figure 7). This figure shows that the in-
hibition pattern of MK-2206 is different in the two
osteosarcoma cell lines, suggesting that other upstream
kinases may be affected by inhibition of Akt with MK-
2206 as well.
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Figure 3 Supervised clustering of kinome profiling results. Supervised clustering on all 49 significantly differentially phosphorylated peptides
identified by the comparison of two osteosarcoma cell lines with two MSC cultures. Peptides are sorted on logFC, from lower phosphorylation to
higher phosphorylation in osteosarcoma cell lines. Orange: higher phosphorylation levels, blue: lower phosphorylation levels.
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Osteosarcoma is a highly genomically unstable tumor.
The identification of specific molecular targets that drive
oncogenesis and that might be targets for therapy may
thereby be hampered. Genome-wide gene expression
profiling of high-grade osteosarcoma cell lines, in fact,
showed an enrichment of differential expression in path-
ways important in genomic stability (Figure 2), with a
role in cell cycle and checkpoint regulation (e.g. p53 sig-
naling, G1/S and G2/M checkpoint regulation), DNA
damage response (e.g. ATM signaling, role of BRCA1 in
DNA damage response), and purine/pyrimidine metab-
olism. Most significantly differentially expressed genes in
these pathways were upregulated, for example DNA-PK,
BRCA1, and CDC25A. Some downregulated genes were
detected as well, such as CDKN1A, which has an inhibi-
tory role on cell cycle progression, and genes downstream
of TP53 (e.g. THBS1 and SERPINE1,e n c o d i n gT S P 1
and PAI-1, respectively). Expression levels of genes in
these pathways in osteosarcoma pre-treatment biopsies
Figure 4 Kinome profiling pathway analysis on the set of significant pathways from gene expression profiling. Stacked bar chart
showing kinome profiling pathway analysis on the subset of pathways which were significant on gene expression profiling. Percentages of
up- (orange), downregulated (blue), not significantly altered genes (gray), and genes which were not present on the microarray (white) are shown.
The –log(adjP)( −log(B-H) p-value) is plotted in orange, and is above 1.3 for adjP< 0.05.
Figure 5 Akt signaling pathway. The Akt signaling pathway in IPA. Blue: significantly lower, orange: significantly higher phosphorylation in
osteosarcoma cell lines, gray, no significant difference in phosphorylation, white: no phosphorylation sites of the particular protein on the
PamGene Ser/Thr chip. Blue lines indicate known downstream phosphorylation by the upstream kinase.
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the same dataset [9] by using the CIN25 signature [29].
IPA transcription factor analysis showed that MYC was
the most significantly activated (z-score of 6.294), and
TP53 the most significantly inactivated (z-score of −7.660)
transcription factor. Other highly predicted activated tran-
scription factors were e.g. E2F1/2/3 (Additional file 6).
These different transcription factors are known to be af-
fected in osteosarcoma [7,9,30]. The role of these tran-
scription factors in cell cycle progression further confirms
the importance of these pathways in osteosarcoma. Im-
portant to note is that we took a different approach to
determine significantly altered pathways from in our
previous publications [9,31]. We only used overlapping
genes with same pattern of expression (both significant
up- or downregulation) in osteosarcoma cell lines versus
both control sets. This approach ensured us that all genes
detected in the enriched pathways are significantly up- or
downregulated in both comparisons, while our previous
analyses described pathways which are significantly al-
tered, but for which the gene list per pathway accounting
for the significant effect may be different. We specifically
took this more conservative approach for our current
study, because we wanted to directly compare the expres-
sion levels and kinase activities of the specific players in
each pathway. We also hypothesized that, using a method
testing the overall aberration of a pathway, it would be
more difficult to pick up specific players to inhibit
pharmacologically. The pathways we detected with this
analysis – pathways playing a role in cell cycling and
genomic instability – were, as expected, also signifi-
cantly affected in the less conservative globaltest ana-
lysis (which tests groups of genes instead of single
genes) reported in our recent BMC Cancer publication
[31] (data not shown).
Given the extreme genomic instability which is notori-
ous in osteosarcoma and has led to the formulation of a
novel genetic mechanism, chromothripsis [32], it is not
surprising that the most prominent pathways are associ-
ated with this signature. Unfortunately pharmacological
targeting of genomic instability is a challenge. Kinome-
wide screens have previously led to the detection of spe-
cific targets for treatment in other sarcoma types
[14,15], and as such a screen can complement us with
extra information on aberrations in the pathways we de-
tected with gene expression analyses, we performed
kinome profiling of osteosarcoma cell lysates. Since the
pathways that were shown to be significantly affected on
mRNA expression mostly contained Ser/Thr kinases, we
selected a Ser/Thr peptide microarray – the Ser/Thr
PamChip®. Pathway analysis on kinome profiling data
showed that 50% of the pathways that were significant
on gene expression data were also significantly enriched
in differential phosphorylation signals (Figure 4). All sig-
nificant peptides were higher phosphorylated in osteo-
sarcoma cell lines, except for a peptide present in
CREB1. Since most of these peptides showed higher
phosphorylation, we expect these pathways to be highly
active, demonstrating higher cell cycling of the tumor
cells, and deregulated responses to DNA damage.
Figure 6 Proliferation of osteosarcoma cell lines was inhibited with different concentrations of MK-2206, for 120 hours. NALM-6, U-2
OS, and HOS showed a dose-dependent inhibition, while 143B did not respond.
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pathways in the kinome data from the entire IPA canon-
ical pathways database, and detected deregulation of the
PI3K/Akt and AMPK signaling pathways. Molecules
downstream of Akt kinases showed higher phosphoryl-
ation (Figure 5), while downstream of AMPK, lower levels
of phosphorylation were detected (Additional file 9). Akt
and AMPK act antagonistically to regulate mTOR signal-
ing through inhibitory and activating phosphorylation of
TSC2, respectively [33]. The Akt pathway is one of the
most commonly affected pathways in cancer, with active
PI3K/Akt signaling leading to excessive cell growth and
proliferation [34,35]. Inhibition of this pathway by target-
ing mTOR with agents such as rapamycin is effective in
some cancer types [36]. In a recent phase II trial in bone
and soft tissue sarcomas, inhibition of mTOR with rida-
forolimus resulted in better progression-free survival [13].
Inhibiting mTOR can, however, also activate a strong nega-
tive feedback loop from S6K1 to enhance Akt signaling
[34,36]. It may, therefore, be more effective to inhibit Akt
itself. Inhibition of Akt was recently tested in a panel of
xenografts of different pediatric cancers, and was most ef-
fective in osteosarcoma, with significant differences in
event-free survival in 6/6 xenografts [19]. In addition,
AMPK activators suppress growth of cell lines of various
tumor types [37].
We treated osteosarcoma cell lines with the allosteric
Akt inhibitor MK-2206 (Selleck Chemicals LLC, Houston,
TX). Inhibition of proliferation was dose-dependent in
U-2 OS (IC50 2.5 μM), but not in 143B (Figure 6). Import-
ant to note is that active Akt signaling can be detected by
kinome profiling in this cell line, but this does not neces-
sarily imply that this pathway can also be fully inhibited,
for example in the case that downstream actors in the
same pathway cause a survival benefit for the cell line. As
143B is derived from the HOS cell line with a KRAS onco-
genic transformation, we determined inhibitory effects of
MK-2206 on HOS as well. HOS responded to MK-2206 in
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Figure 7 Unsupervised clustering of peptides which can be phosphorylated by Akt. Unsupervised clustering depicting differential
phosphorylation of peptides of the PI3K/Akt pathway by cell lysates treated with different concentrations of MK—2206 and for different time
intervals, as compared with untreated cells. Blue: logFC< 0, orange: logFC> 0. Different treatment options are shown in different shades of gray
(from light to dark gray: 1 μM 5, 30, 180, 960, and 10 μM 180 minutes of treatment with MK-2206. Light-green: 143B, dark green: U-2 OS.
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that constitutive Ras/Raf/ERK signaling causes insensitiv-
ity to inhibition of the Akt pathway to MK-2206. Kinome
profiling of cells treated with MK-2206 resulted in differ-
ent phosphorylation patterns in 143B and U-2 OS of pep-
tides of molecules in the PI3K/Akt pathway (Figure 7).
Differences between these cell lines were found in BAD
Ser-99, of which phosphorylation was inhibited after treat-
ment with MK-2206 in the responsive cell line U-2 OS,
but stimulated in 143B, and in BAD Ser-118, where an op-
posite pattern was detected. BAD Ser-99 is the major site
of Akt phosphorylation, while Ser-118 is the major site of
PKA phosphorylation [38]. Opposite patterns were also
detected for TP53 Thr-18 and CDKN1A Thr-145/Ser-146,
of which CDKN1AThr-145 can also be directly phosphor-
ylated by Akt. These results suggest that activity of other
kinases may be affected by inhibition of Akt using MK-
2206, or by MK-2206 itself. This depends on the cellular
context, as we otherwise would not have expected to de-
tect any differences in a paired analysis for the different
conditions in each cell type.
An important finding of our studies is that the PI3K/
Akt and AMPK signaling pathways were detected with
kinome profiling, while mRNA expression profiling did
not result in the identification of these pathways. This
suggests that in osteosarcoma, these pathways are regu-
lated by phosphorylation rather than by transcriptional
activity. Copy number and mRNA expression levels of
Akt family members and their upstream players did not
provide us with a possible mechanism for elevated Akt
activity, although PTEN showed lower, but not signifi-
cantly lower, gene expression levels in both cell lines as
compared with the two MSC controls (data not shown).
Gene expression and protein synthesis imply a long time
commitment of a cell to potential activation of its synthe-
sized proteins. Phosphorylation, on the other hand, pro-
vides a very rapid way to mobilize extra catalytic power
for a short time, and allows fine-tuning of the activation of
ap a t h w a yt ot h en e e d so fac e l l .T h i sd i f f e r e n c ei nt i m e
scale emphasizes the importance of applying different
p l a t f o r m sf o rt h ea n a l y s i so fac o m p l e xt u m o ra sh i g h -
grade osteosarcoma.
Conclusions
In summary, this study shows that genomic stability path-
ways are deregulated on both mRNA and kinome levels,
with most significantly affected genes being upregulated
and/or phosphorylated. Akt was detected as most prob-
ably overactive in osteosarcoma, as downstream peptides
were hyperphosphorylated as compared with MSCs. Akt
inhibitor MK-2206 could inhibit 2/3 osteosarcoma cell
lines. Based on these results, we conclude that attenuating
the PI3K/Akt/mTOR pathway may be effective in a subset
of osteosarcomas.
Description of additional files
The following additional files are available with the on-
line version of this paper. Additional file 1 (.xls) includes
the latest genotyping results of cell lines 143B and U2OS.
Additional file 2 (.pdf) is a figure depicting unsupervised
clustering of gene expression data. Additional file 3 (.pdf) is
a figure showing differentially expressed genes in osteosar-
coma cell lines versus control cell cultures. Additional file 4
(.pdf) depicts unsupervised clustering of all genes present
in the significantly affected pathways determined by IPA
analysis. Additional file 5 (.pdf) depicts Kaplan-Meier ana-
lysis of the different clusters detected in Additional file 4.
Additional file 6 (.xls) is a table including results from the
transcription factor activity prediction analysis in IPA.
Additional file 7 (.pdf) is a Venn diagram showing signifi-
cantly differentially phosphorylated peptides over time.
Additional file 8 (.pdf) shows unsupervised clustering of
technical replicates used in the kinome profiling experi-
ment. Additional file 9 (.pdf) illustrates significant differ-
ential phosphorylation in the AMPK signaling pathway.
Additional file 10 (.pdf) depicts distances between kinome
profiling data of treated and untreated osteosarcoma cells
using unsupervised clustering.
Additional files
Additional file 1: Cell line identification of 143B and U2OS.
Additional file 2: Unsupervised clustering of gene expression data.
Unsupervised hierarchical clustering of mRNA expression data of
osteosarcoma cell lines (black), MSCs (dark gray), and osteoblasts (light
gray), on the 1,000 probes with highest variability in expression. Cell lines
and controls cluster separately. Red: upregulation, green: downregulation.
Additional file 3: Genome-wide gene expression analysis. MA plots
of A osteosarcoma cell lines vs MSCs and B vs osteoblasts (OB). For each
probe, log-intensity ratios (M) are plotted against log-intensity averages
(A). Probes with adjusted P-values< 0.05 are shown in orange, while
probes with adjusted P-values < 0.0001 are shown in red. Probes that do
not show significant differential expression are depicted in black.
Additional file 4: Unsupervised hierarchical clustering on
expression of genes in significantly affected pathways. Hierarchical
clustering of osteosarcoma cell line data (black), control cell lines
(MSC: dark gray, osteoblast: light gray), and data from osteosarcoma
biopsies (blue) on mRNA expression levels of all DE genes present in the
17 significantly affected pathways as determined by IPA. The different
clusters selected for Kaplan-Meier analysis are shown in the upper
dendrogram in different shades of blue, corresponding to the legend of
Additional file 5. Red: upregulation, green: downregulation.
Additional file 5: Kaplan-Meier analysis of different clusters based
on expression of genes in the significantly affected pathways.
Kaplan-Meier metastasis-free survival analysis on data obtained from
patient biopsies which clustered with osteosarcoma cell lines, biopsies
clustering with control cell lines, and an intermediate group, based on
gene expression of genes all present in the 17 significantly affected
pathways (as in Additional file 4). Log-rank test for trend, P= 0.049.
Additional file 6: Transcription factor analysis. Results from the
transcription factor activity prediction analysis in IPA, showing, for each
transcription regulator the molecular type, the logFC of expression of the
transcription factor itself, the predicted activation state (Activated/Inhibited),
the regulation z-score, p-value, and the target molecules present in
the dataset.
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http://www.biomedcentral.com/1755-8794/7/4Additional file 7: Comparison of peptide phosphorylation at
different time points. LIMMA analyses were performed on different time
points, ranging from 0 to 60 minutes of incubation with cell lysates. Venn
diagrams show overlap of significantly differentially phosphorylated
peptides between the consecutive time points.
Additional file 8: Unsupervised hierarchical clustering of the
technical replicates in kinome profiling. Unsupervised hierarchical
clustering on data from all technical replicates that were used for
averaging the kinome profiling data. This clustering was performed on
the significantly differentially phosphorylated peptides that were returned
by a LIMMA analysis on the averages of the technical replicates, as
depicted in Figure 3 of the manuscript. Peptides are sorted on logFC,
from lower phosphorylation to higher phosphorylation in osteosarcoma
cell lines. Orange: higher phosphorylation levels, blue: lower
phosphorylation levels.
Additional file 9: AMPK signaling pathway. The AMPK signaling
pathway in IPA. Blue: significantly lower, orange: significantly higher
phosphorylation in osteosarcoma cell lines, gray, no significant difference
in phosphorylation, white: no phosphorylation sites of the particular
protein on the PamGene Ser/Thr chip. Blue lines indicate known
downstream phosphorylation by the upstream kinase.
Additional file 10: Distances between the kinome profiling data of
cells treated with MK-2206. Unsupervised hierarchical clustering depicting
the distances between data obtained from kinome profiling of cells treated
with different concentrations of MK-2206 and for different time intervals.
1_30: treatment of 30 min with 1 μMo fM K - 2 2 0 6 ,e t c .
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